As demand for new weight loss medications grows, there is increased focus on the insurance coverage landscape
Safety data is similarly limited, with the tolerability of creams and long-term effects sparsely analyzed in the literature
Due to concerns about slowed gastric motility and the risk of aspiration from retained gastric contents, the recommendations are as follows: For patients taking daily doses of GLP-1s, consider discontinuing the medication on the day of the procedure while for those on weekly doses, consider stopping GLP-1s a week prior to the procedure

Ipamorelin: synthetic pentapeptide PEPTIDE SEQUENCE CJC-1295 (no DAC): H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH 2 CHEMICAL STRUCTURE CJC-1295: Ipamorelin: CHEMICAL STRUCTURE CJC-1295 (no DAC): C 152 H 252 N 44 O 42 Ipamorelin: C 38 H 49 N 9 O 5 Mechanism of Action The CJC-1295 (no DAC) + ipamorelin peptide blend stimulates endogenous growth hormone (GH) release by simultaneously activating the growth hormone-releasing hormone receptor (GHRH-R) and the ghrelin/growth hormone secretagogue receptor (GHSR), resulting in synergistic, physiologically pulsatile GH secretion
Liraglutide inhibits endothelial-to-mesenchymal transition and attenuates neointima formation after endovascular injury in streptozotocin-induced diabetic mice